Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
The company has received approval from DCGI to begin patient enrolment and dosing in the country
New targeted therapy offers hope for patients with unresectable or metastatic NSCLC harboring HER2 tyrosine kinase domain activating mutations
Facility designed to advance the next generation of imaging systems
The company is bringing precision therapies for gynaecological cancers
The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries
The projected business potential is around US$ 1 million in the first year
OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors
Subscribe To Our Newsletter & Stay Updated
